One-year outcomes of polyacrylamide hydrogel (Bulkamid) injection in women with stress and mixed urinary incontinence.
Bulkamid
Bulking agents
Mixed urinary incontinence
Stress urinary incontinence
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
11
07
2024
accepted:
12
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
This study aimed to evaluate the efficacy and safety following treatment with Bulkamid for stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI). We retrospectively analyzed data of women diagnosed with SUI or stress-predominant MUI who underwent Bulkamid periurethral injection between November 2020 and January 2023 and completed 12 months of follow-up. The primary outcome of the study was to assess patient satisfaction, which was measured on a four-point scale, ranging from cured to worse, and through validated questionaries such as the International Consultation on Incontinence Questionnaire-short Form (ICIQ-UI SF) and Contilife Quality of Life questionnaire. Of the 70 patients included, 41 (59%) had MUI with predominant stress incontinence. Median age was 59 years (IQR 47-75), with a median BMI of 25 (18-40) and a median number of pregnancies of 2 (0-4). Forty-seven (67%) procedures were performed under sedation and 23 (33%) under local anesthesia. Forty-three (69%) women reported feeling cured or improved at 12 months follow-up and among them, 25 (40%) reported feeling cured. A total of 16 (23%) patients were subsequently treated, in detail 11 (16%) patients underwent MUS positioning, and 5 (7%) had an additional injection of Bulkamid. ICIQ and Contilife QoL showed a significant improvement at 1, 3, 6, and 12 months (all p < 0.001). Bulkamid injections are an effective and safe treatment option for women with SUI or stress-predominant MUI, providing good outcomes at 12 months.
Identifiants
pubmed: 39259255
doi: 10.1007/s00345-024-05221-9
pii: 10.1007/s00345-024-05221-9
doi:
Substances chimiques
Acrylic Resins
0
Bulkamid
0
Hydrogels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
518Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kobashi KC, Vasavada S, Bloschichak A et al (2023) Updates to Surgical Treatment of female stress urinary incontinence (SUI): AUA/SUFU Guideline (2023). J Urol 209(6):1091–1098
doi: 10.1097/JU.0000000000003435
pubmed: 37096580
Nambiar AK, Arlandis S, Bø K et al (2022) European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol 82(1):49–59
doi: 10.1016/j.eururo.2022.01.045
pubmed: 35216856
Hoe V, Haller B, Yao HH, O’Connell HE (2021) Urethral bulking agents for the treatment of stress urinary incontinence in women: a systematic review. Neurourol Urodyn 40(6):1349–1388
doi: 10.1002/nau.24696
pubmed: 34015151
Klarskov N, Lose G (2008) Urethral injection therapy: what is the mechanism of action? Neurourol Urodyn 27(8):789–792
doi: 10.1002/nau.20602
pubmed: 18642372
Zarini E, Supino R, Pratesi G et al (2004) Biocompatibility and tissue interactions of a new filler material for medical use. Plast Reconstr Surg 114:934–942
doi: 10.1097/01.PRS.0000133425.22598.D0
pubmed: 15468401
Abrams P, Avery K, Gardener N, Donovan J, ICIQ Advisory Board (2006) The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 175:1063–1066
doi: 10.1016/S0022-5347(05)00348-4
pubmed: 16469618
Girod I, McCarthy C, Marrel A, De La Loge C, Marquis P (1999) Development and psychometric validation of a quality of life questionnaire in urinary incontinence. In: Abstracts presented to the 6th Annual Conference of ISOQOL, Barcelona, Spain, 3–6 November 1999. Qual Life Res. ;7:658
Lose G, Sørensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T (2010) An open multicenter study of polyacrylamide hydrogel (Bulkamid
doi: 10.1007/s00192-010-1214-1
pubmed: 20645077
pmcid: 2977052
Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S (2013) Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. Arch Gynecol Obstet 288(1):131–137
doi: 10.1007/s00404-013-2718-y
pubmed: 23371485
Sokol ER, Karram MM, Dmochowski R (2014) Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter north American study. J Urol 192(3):843–849
doi: 10.1016/j.juro.2014.03.109
pubmed: 24704117
Brosche T, Kuhn A, Lobodasch K, Sokol ER (2021) Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence. Neurourol Urodyn 40(1):502–508
doi: 10.1002/nau.24589
pubmed: 33410544
pmcid: 7839440
Itkonen Freitas AM, Isaksson C, Rahkola-Soisalo P, Tulokas S, Mentula M, Mikkola TS (2020) Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary in- continence: a randomized clinical trial. J Urol 203(2):372–378
doi: 10.1097/JU.0000000000000517
pubmed: 31479396
Robinson D, Anders K, Cardozo L et al (2003) What do women want? Interpretation of the concept of cure. J Pelvic Med Surg 9:273
doi: 10.1097/01.spv.0000095060.05452.3f